Alnylam Highlights Prospects for Building an Industry-Leading ATTR Amyloidosis Franchise at RNAi Roundtable
Sep 03, 2020
– Company Announces Potential for a Biannual Dosing Regimen Option for its Investigational RNAi Therapeutic Vutrisiran, Providing Support for Further Product Differentiation as a Potential Best-in-Class Agent –
– New Clinical Data Presented at the European Society of Cardiology 2020 Congress Provide Further Evidence that Treatment with Patisiran may Lead to Substantial Reduction in Cardiac Amyloid Burden in ATTR Amyloidosis –
– Company Remains on Track to Report Topline Results from HELIOS-A in Early 2021 and to Complete Enrollment in APOLLO-B in 2021; HELIOS-B Enrollment Expanding Globally –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 3, 2020--
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, will host an “RNAi Roundtable” webinar today at 12:00 p.m. ET, which will focus on progress across its ATTR amyloidosis programs. The Company will discuss the potential for a biannual subcutaneous dosing regimen for vutrisiran, as well as discuss ongoing Phase 3 development for patisiran and vutrisiran across the APOLLO-B, HELIOS-A, and HELIOS-B studies. The Company also announced data from a clinical study evaluating the impact of patisiran and diflunisal, a TTR stabilizer, on cardiac amyloid burden. These data, presented at the European Society of Cardiology (ESC) 2020 Congress, suggest that treatment with patisiran may lead to cardiac amyloid regression in patients with cardiomyopathy associated with ATTR amyloidosis.
“We believe we have the potential to build an industry-leading franchise of medicines for the treatment of ATTR amyloidosis, and we look forward to highlighting our progress in our RNAi Roundtable later today. Amongst other achievements, we will discuss the opportunity for a biannual dosing regimen option for vutrisiran providing further differentiation to achieve a potential best-in-class profile. In addition, we will update on ongoing progress for our TTR programs in our APOLLO-B, HELIOS-A, and HELIOS-B Phase 3 studies of patisiran and vutrisiran,” said Eric Green, Senior Vice President and General Manager of the TTR Program. “Moreover, we will summarize new recently presented data supporting the potential for patisiran to achieve a substantial reduction in cardiac amyloid burden in ATTR amyloidosis, with associated functional and biomarker improvements. We remain committed to developing additional therapeutic options for the treatment of ATTR amyloidosis and driving innovation that can potentially help improve patient outcomes and treatment experience.”
Vutrisiran Clinical Development Program
Vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis, is currently being evaluated in the HELIOS Phase 3 program. HELIOS-A is a randomized, open-label, global multi-center study evaluating the efficacy and safety of vutrisiran in patients with hATTR amyloidosis with polyneuropathy; this study is fully enrolled. The Company reiterates that topline results from HELIOS-A are expected to be announced in early 2021. In this study, patients receive 25mg of vutrisiran subcutaneously once every 12 weeks.
Alnylam announces today that it has obtained clinical pharmacology data supporting the potential for a biannual subcutaneous dosing regimen for vutrisiran. Specifically, new analyses show that a biannual 50mg dosing regimen is expected to achieve comparable TTR knockdown to results with a 25mg quarterly dosing regimen and to a once every three weekly intravenous dosing regimen employed with patisiran. A biannual dosing regimen option for vutrisiran is expected to support further product differentiation for a potential best-in-class profile, and the Company plans to work with regulatory authorities in late 2020 to determine the most efficient regulatory path forward.
The Company affirmed that enrollment continues in the HELIOS-B Phase 3 study, a randomized, double-blind, placebo-controlled, global multi-center study evaluating the efficacy and safety of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy. In this study, patients receive 25mg of vutrisiran subcutaneously or placebo once every 12 weeks, and the primary endpoint is mortality and CV hospitalization at 30 months with a planned interim analysis. Alnylam has implemented steps to accelerate enrollment in HELIOS-B to make up for slowed patient accrual during the COVID-19 pandemic.
In April 2020, Alnylam announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to vutrisiran for the treatment of the polyneuropathy of hereditary ATTR (hATTR) amyloidosis.
Patisiran Clinical Development Program
Patisiran is being investigated for the treatment of ATTR amyloidosis with cardiomyopathy in the APOLLO-B study. APOLLO-B is a Phase 3, randomized, double-blind, placebo-controlled, global multi-center study designed to evaluate the efficacy and safety of patisiran in patients with ATTR amyloidosis with cardiomyopathy. Enrollment in APOLLO-B continues, and the study enrollment is expected to be completed in 2021.
Of interest, a study of 32 patients with hATTR cardiac amyloidosis – presented at ESC 2020 held virtually August 29 - September 1, 2020 – provides encouraging evidence of the potential for substantial reduction in cardiac amyloid burden in patients treated with patisiran. The non-randomized study, led by the University College Hospital in the UK, was conducted to evaluate the impact of patisiran and diflunisal, a TTR stabilizer, on cardiac amyloid load as measured by cardiac magnetic resonance (CMR) and T1 mapping, in patients with hATTR amyloidosis. Patients were assessed with echocardiogram, CMR, NT-proBNP, and 6-minute walk test (6MWT) at baseline and at one year. At the one-year time point, there was a substantial reduction in cardiac amyloid burden in 45% of patients who received patisiran (N=16). Patients treated with patisiran also showed a reduction in extracellular volume fraction (ECV) compared to an increase in ECV in the control group (n=16). These findings show the potential for CMR to be used to track response in treated patients with ATTR cardiac amyloidosis. Patients treated with patisiran also showed an improvement in change in 6MWT at one year, compared to patients in the control group. According to the authors, combination therapy with an RNAi therapeutic against transthyretin and a TTR stabilizing agent may be synergistic given enhanced stoichiometry of TTR stabilizers in the face of markedly reduced plasma transthyretin concentration.
Today’s RNAi Roundtable webinar can be accessed at www.alnylam.com/events or on the Capella section of the Alnylam website.
About ONPATTRO® (patisiran)
ONPATTRO is an RNAi therapeutic that was approved in the United States and Canada for the treatment of the polyneuropathy of hATTR amyloidosis in adults. ONPATTRO is also approved in the European Union, Switzerland and Brazil for the treatment of hATTR amyloidosis in adults with Stage 1 or Stage 2 polyneuropathy, and in Japan for the treatment of hATTR amyloidosis with polyneuropathy. ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin (TTR). It is designed to target and silence TTR messenger RNA, thereby blocking the production of TTR protein before it is made. ONPATTRO blocks the production of TTR in the liver, reducing its accumulation in the body’s tissues in order to halt or slow down the progression of the polyneuropathy associated with the disease. For more information about ONPATTRO, visit ONPATTRO.com.
ONPATTRO (patisiran) lipid complex injection Important Safety Information
Infusion-related reactions (IRRs) have been observed in patients treated with ONPATTRO. In a controlled clinical study, 19 percent of ONPATTRO-treated patients experienced IRRs, compared to 9 percent of placebo-treated patients. The most common symptoms of IRRs with ONPATTRO were flushing, back pain, nausea, abdominal pain, dyspnea, and headache.
To reduce the risk of IRRs, patients should receive premedication with a corticosteroid, acetaminophen, and antihistamines (H1 and H2 blockers) at least 60 minutes prior to ONPATTRO infusion. Monitor patients during the infusion for signs and symptoms of IRRs. If an IRR occurs, consider slowing or interrupting the infusion and instituting medical management as clinically indicated. If the infusion is interrupted, consider resuming at a slower infusion rate only if symptoms have resolved. In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed.
Reduced Serum Vitamin A Levels and Recommended Supplementation
ONPATTRO treatment leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking ONPATTRO. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with ONPATTRO, as serum levels do not reflect the total vitamin A in the body.
Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g. night blindness).
The most common adverse reactions that occurred in patients treated with ONPATTRO were upper respiratory-tract infections (29 percent) and infusion-related reactions (19 percent).
For additional information about ONPATTRO, please see the full Prescribing Information.
About hATTR Amyloidosis
Hereditary transthyretin (TTR)-mediated amyloidosis (hATTR) is an inherited, progressively debilitating, and often fatal disease caused by mutations in the TTR gene. TTR protein is primarily produced in the liver and is normally a carrier of vitamin A. Mutations in the TTR gene cause abnormal amyloid proteins to accumulate and damage body organs and tissue, such as the peripheral nerves and heart, resulting in intractable peripheral sensory-motor neuropathy, autonomic neuropathy, and/or cardiomyopathy, as well as other disease manifestations. hATTR amyloidosis, represents a major unmet medical need with significant morbidity and mortality affecting approximately 50,000 people worldwide. The median survival is 4.7 years following diagnosis, with a reduced survival (3.4 years) for patients presenting with cardiomyopathy.
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines, known as RNAi therapeutics, is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), approved in the U.S., EU, Canada, Japan, Switzerland and Brazil, and GIVLAARI® (givosiran), approved in the U.S., EU, and Brazil. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its “Alnylam 2020” strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn.
Alnylam Forward Looking Statements
Various statements in this release, including, without limitation, Alnylam's views and plans with respect to the potential for RNAi therapeutics, including patisiran and vutrisiran, as monotherapies or in combination with a TTR stabilizing agent, Alnylam’s prospects for building an industry-leading ATTR amyloidosis franchise, expected timing for completing the ongoing APOLLO B Phase 3 study and completing enrollment and availability of results in the ongoing HELIOS Phase 3 program, and expectations regarding the achievement of its “Alnylam 2020” guidance for the advancement and commercialization of RNAi therapeutics, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation: the direct or indirect impact of the COVID-19 global pandemic or a future pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays in diagnoses of rare diseases, initiation or continuation of treatment for diseases addressed by Alnylam products, or in patient enrollment in clinical trials, potential supply chain disruptions, and other potential impacts to Alnylam’s business, the effectiveness or timeliness of steps taken by Alnylam to mitigate the impact of the pandemic, and Alnylam’s ability to execute business continuity plans to address disruptions caused by the COVID-19 or a future pandemic; Alnylam's ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates, including patisiran and vutrisiran; the pre-clinical and clinical results for its product candidates, which may not be replicated or continue to occur in other subjects or in additional studies or otherwise support further development of product candidates for a specified indication or at all; actions or advice of regulatory agencies, which may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional pre-clinical and/or clinical testing; delays, interruptions or failures in the manufacture and supply of its product candidates or its marketed products, including ONPATTRO, GIVLAARI, inclisiran, lumasiran and vutrisiran; obtaining, maintaining and protecting intellectual property; intellectual property matters including potential patent litigation relating to its platform, products or product candidates; obtaining regulatory approval for its product candidates, including lumasiran and inclisiran, and maintaining regulatory approval and obtaining pricing and reimbursement for its products, including ONPATTRO and GIVLAARI; progress in continuing to establish a commercial and ex-United States infrastructure; successfully launching, marketing and selling its approved products globally, including ONPATTRO and GIVLAARI and achieving net product revenues for ONPATTRO within its revised expected range during 2020; Alnylam’s ability to successfully expand the indication for ONPATTRO in the future; competition from others using technology similar to Alnylam's and others developing products for similar uses; Alnylam's ability to manage its growth and operating expenses within the reduced ranges of guidance provided by Alnylam through the implementation of further discipline in operations to moderate spend and its ability to achieve a self-sustainable financial profile in the future without the need for future equity financing; Alnylam’s ability to establish and maintain strategic business alliances and new business initiatives ; Alnylam's dependence on third parties, including Regeneron, for development, manufacture and distribution of certain products, including eye and CNS products, Ironwood, for assistance with the education about and promotion of GIVLAARI, and Vir for the development of ALN-COV and other potential RNAi therapeutics targeting SARS-CoV-2 and host factors for SARS-CoV-2; the outcome of litigation; the risk of government investigations; and unexpected expenditures, as well as those risks more fully discussed in the "Risk Factors" filed with Alnylam's most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings that Alnylam makes with the SEC. In addition, any forward-looking statements represent Alnylam's views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200903005260/en/
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)
Source: Alnylam Pharmaceuticals, Inc.